share_log

藥明康德：翌日披露報表

WUXI APPTEC: Next Day Disclosure Return

香港交易所 ·  Apr 8 05:05
Summary by Moomoo AI
無錫藥明康德新藥開發股份有限公司（药明康德）於2024年3月11日至4月8日期間，通過上海證券交易所回購共計7,319,317股A股股份。該公司股份回購行動始於2024年3月11日，首次回購937,079股，並於4月8日回購434,846股作為最後一次交易，每股回購價格介於RMB 45.78至RMB 57.32之間。根據香港聯合交易所有限公司證券上市規則，公司於4月8日向香港聯交所提交翌日披露報表，披露已發行股本變動情況。該系列股份回購未涉及股份註銷，並由公司董事李革正式呈交。
無錫藥明康德新藥開發股份有限公司（药明康德）於2024年3月11日至4月8日期間，通過上海證券交易所回購共計7,319,317股A股股份。該公司股份回購行動始於2024年3月11日，首次回購937,079股，並於4月8日回購434,846股作為最後一次交易，每股回購價格介於RMB 45.78至RMB 57.32之間。根據香港聯合交易所有限公司證券上市規則，公司於4月8日向香港聯交所提交翌日披露報表，披露已發行股本變動情況。該系列股份回購未涉及股份註銷，並由公司董事李革正式呈交。
Wuxi Pharmaceutical Ming Kand New Drug Development Co., Ltd. (Pharmaceutical Ming Kand) repurchased a total of 7,319,317 A-shares through the Shanghai Stock Exchange between March 11 and April 8, 2024. The Company's share repurchase operation began on March 11, 2024, with a first repurchase of 937,079 shares and a final repurchase of 434,846 shares on April 8, with a repurchase price of RMB 45.78 to RMB 57.32 per share. Pursuant to the Listing Rules of the Stock Exchange of Hong Kong Limited, the Company filed a next-day disclosure statement with the Stock Exchange on 8 April, disclosing the changes in issued share capital. The share repurchase of the series did not involve a share write-off and was formally presented by Mr. Li Keung, the Company's director.
Wuxi Pharmaceutical Ming Kand New Drug Development Co., Ltd. (Pharmaceutical Ming Kand) repurchased a total of 7,319,317 A-shares through the Shanghai Stock Exchange between March 11 and April 8, 2024. The Company's share repurchase operation began on March 11, 2024, with a first repurchase of 937,079 shares and a final repurchase of 434,846 shares on April 8, with a repurchase price of RMB 45.78 to RMB 57.32 per share. Pursuant to the Listing Rules of the Stock Exchange of Hong Kong Limited, the Company filed a next-day disclosure statement with the Stock Exchange on 8 April, disclosing the changes in issued share capital. The share repurchase of the series did not involve a share write-off and was formally presented by Mr. Li Keung, the Company's director.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more